Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine.
Lorenzo Villa Zapata, PhD
Advertisement
Articles by Lorenzo Villa Zapata, PhD
The authors explore the economic impact and accessibility challenges of new Alzheimer disease drugs under the Inflation Reduction Act, with emphasis on Medicare, pricing, and health care equity.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
US Employer Health Care Costs Projected to Rise 9.5% in 2027
2
5 Things to Know About the FDA's Peptide Reversal
3
Rural Patients Face Gaps in Hospice Access, Care Intensity
4
5 Things to Know About Chronic Hand Eczema and Its Evolving Treatment Landscape
5